{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:39:06Z","timestamp":1782232746986,"version":"3.54.5"},"reference-count":53,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2015,1,16]],"date-time":"2015-01-16T00:00:00Z","timestamp":1421366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2015,1,16]],"date-time":"2015-01-16T00:00:00Z","timestamp":1421366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Nucleic Acid Therapeutics"],"published-print":{"date-parts":[[2015,4,1]]},"abstract":"<jats:p>Oligonucleotide analogs have provided novel therapeutics targeting various disorders. However, their poor cellular uptake remains a major obstacle for their clinical development. Negatively charged oligonucleotides, such as 2\u2032-O-Methyl RNA and locked nucleic acids have in recent years been delivered successfully into cells through complex formation with cationic polymers, peptides, liposomes, or similar nanoparticle delivery systems. However, due to the lack of electrostatic interactions, this promising delivery method has been unsuccessful to date using charge-neutral oligonucleotide analogs. We show here that lipid-functionalized cell-penetrating peptides can be efficiently exploited for cellular transfection of the charge-neutral oligonucleotide analog phosphorodiamidate morpholino. The lipopeptides form complexes with splice-switching phosphorodiamidate morpholino oligonucleotide and can be delivered into clinically relevant cell lines that are otherwise difficult to transfect while retaining biological activity. To our knowledge, this is the first study to show delivery through complex formation of biologically active charge-neutral oligonucleotides by cationic peptides.<\/jats:p>","DOI":"10.1089\/nat.2014.0511","type":"journal-article","created":{"date-parts":[[2015,1,16]],"date-time":"2015-01-16T14:35:28Z","timestamp":1421418928000},"page":"65-77","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides"],"prefix":"10.1177","volume":"25","author":[{"given":"Peter","family":"J\u00e4rver","sequence":"first","affiliation":[{"name":"Medical Research Council","place":["United Kingdom"]},{"name":"Karolinska University Hospital","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman M.","family":"Zaghloul","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital","place":["Sweden"]},{"name":"Alexandria University","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey A.","family":"Arzumanov","sequence":"additional","affiliation":[{"name":"Medical Research Council","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer F.","family":"Saleh","sequence":"additional","affiliation":[{"name":"Medical Research Council","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Mcclorey","sequence":"additional","affiliation":[{"name":"University of Oxford","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan M.","family":"Hammond","sequence":"additional","affiliation":[{"name":"University of Oxford","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"H\u00e4llbrink","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00fclo","family":"Langel","sequence":"additional","affiliation":[{"name":"Department of Neurochemistry, Stockholm University, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.I. Edvard","family":"Smith","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.A.","family":"Wood","sequence":"additional","affiliation":[{"name":"University of Oxford","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Gait","sequence":"additional","affiliation":[{"name":"Medical Research Council","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"El Andaloussi","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital","place":["Sweden"]},{"name":"University of Oxford","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,1,16]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"1628","article-title":"Antisense technologies","volume":"270","author":"Kurreck J","year":"2003","unstructured":"Kurreck J. (2003). Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem, 270:1628\u20131644.","journal-title":"Improvement through novel chemical modifications. Eur J Biochem"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/25.16.3290"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22243"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2006.02.012"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)34080-2"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/414729"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.4161\/adna.18739"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-429-2_6"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc200460t"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.249-255.2005"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn541"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60756-3"},{"key":"e_1_3_3_14_2","first-page":"1","article-title":"Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment","author":"Betts C","year":"2012","unstructured":"Betts C, , Saleh AF, , Arzumanov AA, , Hammond SM, , Godfrey C, , Coursindel T, , Gait MJ, and Wood MJ. (2012). Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol Ther Nucleic, Acid, 1:e38","journal-title":"Mol Ther Nucleic"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.54"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1158"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76175"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2013.08.005"},{"key":"e_1_3_3_19_2","first-page":"59","article-title":"Targeting mRNA Splicing as a Potential Treatment for Duchenne Muscular Dystrophy","volume":"74","author":"Kole R","year":"2012","unstructured":"Kole R, and Leppert BJ. (2012). Targeting mRNA Splicing as a Potential Treatment for Duchenne Muscular Dystrophy. Discov Med, 74:59\u201369.","journal-title":"Discov Med"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2013.850030"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90667-F"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.152.2.557"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92206-7"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0598-63"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddp030"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/ahg.12031"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10059-012-0005-6"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90579-4"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/10408363.2012.658906"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/402369"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc015508l"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/ar200256e"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302128"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1261\/rna.2252206"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2008.11.025"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2009.08.028"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq1299"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc4002757"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1257"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr072"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.26.4.1333-1346.2006"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.276"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddg196"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-6502com"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp200481g"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.13.2860"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1006\/dbio.1994.1103"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0073-2"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.287"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2005.04.010"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc100275r"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1039\/c3ob41659c"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20070507"}],"container-title":["Nucleic Acid Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/nat.2014.0511","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/nat.2014.0511","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/nat.2014.0511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:59:22Z","timestamp":1777669162000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/nat.2014.0511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,16]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4,1]]}},"alternative-id":["10.1089\/nat.2014.0511"],"URL":"https:\/\/doi.org\/10.1089\/nat.2014.0511","relation":{},"ISSN":["2159-3337","2159-3345"],"issn-type":[{"value":"2159-3337","type":"print"},{"value":"2159-3345","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,16]]}}}